DCTN6

Across TCGA pan-cancer cohorts, DCTN6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DCTN6 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DCTN6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DCTN6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where DCTN6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.688	0.340	.002	21	view →
LUAD	DFS	Quartile	All	0.803	0.996	.001	14	view →
CCRCC	DFS	Quartile	II,III,IV	0.853	0.473	.022	11	view →
HNSC	OS	Tertile	All	0.897	0.771	.025	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DCTN6–PDAC (OS)

Open the PDAC breakdown →